Eli Lilly and Company (NYSE:LLY) Trading Down 1.2%

Eli Lilly and Company (NYSE:LLY) shares were down 1.2% during mid-day trading on Thursday . The stock traded as low as $764.60 and last traded at $767.68. Approximately 730,834 shares were traded during trading, a decline of 76% from the average daily volume of 3,038,991 shares. The stock had previously closed at $776.75.

Analyst Ratings Changes

A number of brokerages recently commented on LLY. Morgan Stanley upped their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Truist Financial upped their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, Bank of America increased their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Stock Down 2.4 %

The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The firm has a market cap of $720.37 billion, a price-to-earnings ratio of 111.71, a price-to-earnings-growth ratio of 1.58 and a beta of 0.37. The firm has a 50-day moving average price of $762.03 and a two-hundred day moving average price of $669.96.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The business’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the company earned $1.62 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 13.5 earnings per share for the current year.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently modified their holdings of the business. FinTrust Capital Advisors LLC boosted its stake in shares of Eli Lilly and Company by 19.0% in the first quarter. FinTrust Capital Advisors LLC now owns 2,007 shares of the company’s stock valued at $1,561,000 after buying an additional 321 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in Eli Lilly and Company by 14.7% during the first quarter. Daiwa Securities Group Inc. now owns 107,114 shares of the company’s stock worth $83,330,000 after purchasing an additional 13,694 shares in the last quarter. Graypoint LLC boosted its position in Eli Lilly and Company by 3.5% during the first quarter. Graypoint LLC now owns 7,662 shares of the company’s stock worth $5,961,000 after purchasing an additional 258 shares in the last quarter. Consolidated Planning Corp boosted its position in Eli Lilly and Company by 1.7% during the first quarter. Consolidated Planning Corp now owns 1,166 shares of the company’s stock worth $907,000 after purchasing an additional 19 shares in the last quarter. Finally, Pittenger & Anderson Inc. boosted its position in Eli Lilly and Company by 123.2% during the first quarter. Pittenger & Anderson Inc. now owns 944 shares of the company’s stock worth $734,000 after purchasing an additional 521 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.